典型文献
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
文献摘要：
Inducing durable and effective immunity against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)via vaccination is essential to combat the current pandemic of coronavirus disease 2019(COVID-19).It has been noticed that the strength of anti-COVID-19 vaccination-induced immunity fades over time,which calls for an additional vaccination regime,as known as booster immunization,to restore immunity among previously vaccinated populations.Here we report a pilot open-label trial of a third dose of BBIBP-CorV,an inactivated SARS-CoV-2 vaccine(Vero cell),on 136 participants aged between 18 to 63 years.Safety and immunogenicity in terms of neutralizing antibody titers and cytokine/chemokine responses were analyzed as the main endpoint until day 28.While systemic reactogenicity was either absent or mild,SARS-CoV-2-specific neutralizing antibody titers rapidly arose in all participants within 4 weeks,surpassing the peak antibody titers elicited by the initial two-dose immunization regime.Broad increases of cellular immunity-associated cytokines and chemokines were also detected in the majority of participants after the third vaccination.Furthermore,in an exploratory study,a newly developed recombinant protein vaccine,NVSI-06-08(CHO Cells),was found to be safe and even more effective than BBIBP-CorV in eliciting humoral immune responses in BBIBP-CorV-primed individuals.Together,these results indicate that a third immunization schedule with either homologous or heterologous vaccine showed favorable safety profiles and restored potent SARS-CoV-2-specific immunity,providing support for further trials of booster vaccination in larger populations.
文献关键词：
中图分类号：
作者姓名：
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang
作者机构：
China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
文献出处：
引用格式：
[1]Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-.Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults)[J].医学前沿,2022(01):93-101
A类：
reactogenicity,NVSI
B类：
Early,assessment,safety,immunogenicity,third,dose,booster,immunization,Chinese,adults,Inducing,durable,effective,immunity,against,severe,acute,respiratory,syndrome,coronavirus,SARS,CoV,via,vaccination,essential,combat,current,pandemic,disease,It,has,been,noticed,that,strength,induced,fades,over,which,calls,additional,regime,known,among,previously,vaccinated,populations,Here,report,pilot,open,label,BBIBP,CorV,inactivated,vaccine,Vero,participants,aged,between,years,Safety,terms,neutralizing,antibody,titers,responses,were,analyzed,main,endpoint,until,day,While,systemic,was,either,absent,mild,specific,rapidly,arose,within,weeks,surpassing,peak,elicited,by,initial,two,Broad,increases,cellular,associated,cytokines,chemokines,also,detected,majority,after,Furthermore,exploratory,study,newly,developed,recombinant,protein,CHO,Cells,found,even,than,eliciting,humoral,immune,primed,individuals,Together,these,results,indicate,schedule,homologous,heterologous,showed,favorable,profiles,restored,potent,providing,support,further,trials,larger
AB值：
0.590828
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
